Baidu
map

转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Clinica Chimica Acta：一种性能优秀的癌症筛查包可用于早期和急性淋巴细胞白血病检测？

2019-11-23 MedSci MedSci原创

急性淋巴细胞白血病
关注

本研究介绍一套用于早期检测急性淋巴细胞白血病(ALL)癌症的生物传感器。

本研究介绍一套用于早期检测急性淋巴细胞白血病(ALL)癌症的生物传感器。这里提出的癌症筛选包包括DNA传感器和aptasensor作为两种主要的生物传感器。两种生物传感器同时使用不仅可以检测突变基因的存在，还可以检测癌症的生物标志物。在目前的工作中，传感器的组合被用来检测作为突变基因的BCR-ABL1和作为癌症的生物标志物的CEA的存在，这种能力使包易于早期和一定程度上检测到急性淋巴细胞白血病。

为了构建DNA传感器和aptasensor，本研究使用了一种由电合成碳量子点和生物合成金纳米颗粒组成的纳米复合材料。这些生物传感器的构建采用四种不同的电化学方法，包括DPV(微分脉冲伏安法)、EIS(电化学阻抗谱法)、CV(循环伏安法)和计时安培法。

在生物传感器上用作电活性探针的邻苯二酚溶液的峰值电流与目标DNA和目标抗原的浓度的对数线性相关，范围为10 pM至100µμM和1µpg mL-1至 0.001 g mL-1的检出限分别为1.5 pM和0.26 pg mL-1，这是相当不错的结果。

原始出处：

Mohammad Mazloum-Ardakani，Behnaz Barazesh，A distinguished cancer-screening package containing a DNA sensor and an aptasensor for early and certain detection of acute lymphoblastic leukemia

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997964, encodeId=ce7f199e96431, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Aug 06 07:03:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849789, encodeId=8ec01849e893b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 18 06:03:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302279, encodeId=6f6413022e921, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536140, encodeId=e54a153614059, content=<a href='/topic/show?id=d0c6e1458e2' target=_blank style='color:#2F92EE;'>#癌症筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71458, encryptionId=d0c6e1458e2, topicName=癌症筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46ed12663026, createdName=yangwen5713, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2020-08-06 sunyl07

    #淋巴细胞白血病#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1997964, encodeId=ce7f199e96431, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Aug 06 07:03:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849789, encodeId=8ec01849e893b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 18 06:03:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302279, encodeId=6f6413022e921, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536140, encodeId=e54a153614059, content=<a href='/topic/show?id=d0c6e1458e2' target=_blank style='color:#2F92EE;'>#癌症筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71458, encryptionId=d0c6e1458e2, topicName=癌症筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46ed12663026, createdName=yangwen5713, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2020-05-18 windight

    #CTA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1997964, encodeId=ce7f199e96431, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Aug 06 07:03:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849789, encodeId=8ec01849e893b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 18 06:03:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302279, encodeId=6f6413022e921, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536140, encodeId=e54a153614059, content=<a href='/topic/show?id=d0c6e1458e2' target=_blank style='color:#2F92EE;'>#癌症筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71458, encryptionId=d0c6e1458e2, topicName=癌症筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46ed12663026, createdName=yangwen5713, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2019-11-25 wetgdt

    #淋巴细胞#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1997964, encodeId=ce7f199e96431, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Aug 06 07:03:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849789, encodeId=8ec01849e893b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 18 06:03:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302279, encodeId=6f6413022e921, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536140, encodeId=e54a153614059, content=<a href='/topic/show?id=d0c6e1458e2' target=_blank style='color:#2F92EE;'>#癌症筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71458, encryptionId=d0c6e1458e2, topicName=癌症筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46ed12663026, createdName=yangwen5713, createdTime=Mon Nov 25 12:03:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2019-11-25 yangwen5713

    #癌症筛查#

    0

相关资讯

NCCN临床实践指南：急性淋巴细胞白血病（2019.V1）

2019年4月，美国国家综合癌症网络(NCCN)发布了急性淋巴细胞白血病2019年第1版，指南主要内容涉及： 指南更新摘要 诊断 检查和风险分层 Ph+急性淋巴细胞白血病（ALL）诱导治疗和巩固治疗 成人Ph+ ALL诱导治疗和巩固治疗 Ph- ALL 诱导治疗和巩固治疗 成人Ph- ALL 诱导治疗和巩固治疗 监测 复发/难治性疾病的治疗 主要ALL亚型标准免疫分型 髓外评估和治疗 维持疗法 系

NCCN临床实践指南：急性淋巴细胞白血病（2019.V2）

2019年5月，美国国家综合癌症网络(NCCN)发布了急性淋巴细胞白血病2019年第2版，指南主要内容涉及： 指南更新摘要 诊断 检查和风险分层 Ph+急性淋巴细胞白血病（ALL）诱导治疗和巩固治疗 成人Ph+ ALL诱导治疗和巩固治疗 Ph- ALL 诱导治疗和巩固治疗 成人Ph- ALL 诱导治疗和巩固治疗 监测 复发/难治性疾病的治疗 B-ALL发生风险 髓外受累的评估和治疗 维持疗法 系统

Blood：唐氏综合征患儿急性淋巴细胞白血病的遗传易感性

唐氏综合症(DS)患儿发生急性淋巴细胞白血病(ALL)的风险增加了20倍，并表现出明显的体细胞突变特征，包括约50%的病例发生CRLF2重排，但遗传基因变异在所有DS患儿ALL易感性中的作用尚不清楚。

JCO：Interfant-06研究治疗1岁以下婴儿急性淋巴细胞白血病结果披露

婴儿急性淋巴细胞白血病（ALL）是一种罕见的白血病，在年长儿童中KMT2A基因重排仅有1%~2%,但在婴儿中出现概率可达75%左右。为了解决相关的治疗问题，需要大规模的国际合作。近期发表在JCO 杂志上的一项国际III期随机研究Interfant-06试图探索在1岁以下婴儿急性淋巴细胞白血病的治疗，让我们一起来看看吧。

Autolus双靶头CAR-T疗法AUTO3治疗急性淋巴细胞白血病，获得FDA授予的孤儿药物指定

Autolus Therapeutics公司周二宣布，该公司的靶向CD19和CD22的双靶头嵌合抗原受体（CAR），用于治疗急性淋巴细胞白血病（ALL），获得了FDA的一项孤儿药指定。首席执行官Christian Itin表示，"我们相信，通过解决抗原逃逸这一患者复发的常见原因，AUTO3有可能成为儿科ALL的最佳疗法。"

Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定

Autolus Therapeutics宣布，美国食品和药物管理局（FDA）已授予其下一代程序化T细胞疗法AUTO1的孤儿药指定，用于治疗急性淋巴细胞白血病（ALL）患者。

Baidu
map
Baidu
map
Baidu
map